SciELO - Scientific Electronic Library Online

 
vol.38 número4Effect of a standardized approach on infants hospitalized for apparent life threatening eventsEffects of exercise on the cognition of older women treated with lovastatin índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Biomédica

versão impressa ISSN 0120-4157

Resumo

MATIZ, Germán Eduardo; TRUJILLO, Mary; PEREZ, Diana Alexandra  e  BAENA, Yolima. In vitro evaluation of the interchangeability of different brands of diclofenac sodium tablets available in the Colombian market. Biomédica [online]. 2018, vol.38, n.4, pp.486-495. ISSN 0120-4157.  https://doi.org/10.7705/biomedica.v38i4.3988.

Introduction:

Diclofenac sodium is classified as a non-steroidal anti-inflammatory drug. As diclofenac is an over-the-counter drug, its use among patients cannot be monitored by health teams in follow-up sessions. Given the multiple sources of diclofenac sodium, their interchangeability must be investigated, particularly in the form of in vitro studies, which are the most practical research type and entail minimal ethical commitment.

Objectives:

To determine the interchangeability of the different commercial brands of diclofenac sodium relative to the innovative product, this work carries out an in vitro study of eight commercial products of diclofenac sodium (50 mg) following the guidelines of the Biopharmaceutical Classification System.

Materials and methods:

Physical and chemical tests were developed following the guidelines of the 39th edition of the United States Pharmacopoeia. An analytical methodology was validated for the quantification of diclofenac according to the current pharmacopoeia and the Q2 guideline ofthe International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Dissolution profiles and their analyseswere governed by the regulations established by the World Health Organization and the national regulations.

Results:

All the products passed the physical tests. In the dissolution assays, the acid stage was overcome by all brands, but in the alkaline stage, one brand failed. The analysis of the similarities revealed that only one product was equivalent to the innovator and that three were supra-available, although these brands could also be considered equivalent to the innovator.

Conclusions:

Of the eight brands evaluated, three failed the test forthe active principle and the percentage of dissolution. Only one brand was found to be interchangeable with the innovator, and three were identified to besupra-availableand, thus, they do not present a risk for patients.

Palavras-chave : Diclofenac; bioequivalent drugs; interchange of drugs; drug liberation; dissolution.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )